Long-term exposure to natalizumab during pregnancy - a prospective case series from the German Multiple Sclerosis and Pregnancy Registry (P2.101)

Conclusions:Fewer newborns in the <gw24group and <gw30group were born with HA in comparison with >gw30group, but significantly more relapses occurred in the <gw24group. If necessary NTZ withdrawal around 30th gw seems to be the best option for mother and child but more cases are needed to ensure a beneficial effect of NTZ withdrawal before 30th gw on hematological abnormalities.Study Supported by: The German Multiple Sclerosis and Pregnancy registry was partly supported by Bayer Healthcare, Biogen Idec Germany, Merck Serono, Novartis Pharma, Teva Pharma, and Sanofi-Aventis Genzyme Pharmaceuticals.Disclosure: Dr. Hellwig has received personal compensation for activities with Bayer Schering, Biogen Idec, Merck Serono, Teva Aventis and Novartis. Dr. Hellwig has received research support from the German Research Foundation. Dr. Thiel has nothing to disclose. Dr. Meinl has received personal compensation for activities with Bayer Pharmaceuticals Corp. Dr. Gold has received personal compensation for activities with Bayer HealthCare, Biogen, Merck Serono, Novartis, and Teva Neuroscience as a speaker. Dr. Gold has received personal compensation in an editorial capacity for Sage. Dr. Gold has received research support from Bayer HealthCare, Biogen, Merck Serono, Novartis, and Teva Neuroscience. Dr. Kümpfel has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: MS and CNS Inflammatory Disease Poster Discussion Session Source Type: research